Cisplatin plus 5-FU for the treatment of adenocarcinoma of the colon

P. J. Loehrer, L. H. Einhorn, S. D. Williams, S. L. Hui, N. C. Estes, K. Pennington

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Cisplatin plus 5-FU appears to have significant additive activity in various tumors, such as head and neck carcinoma and esophageal cancer. A partial explanation for this may be drug synergism, which has been noted in the L1210 leukemia model. Based on these data, a prospective trial of weekly bolus 5-FU (15 mg/kg) and cisplatin (60 mg/m2) given every 3 weeks was initiated at Indiana University. Forty-one patients, of whom 38 are fully evaluable for response, were treated with these two drugs. Ten partial and one complete response (complete + partial response rate = 29%) were observed in the 38 evaluable patients. Thirteen additional patients had stable disease for ≥ 3 months. The median durations of remission and survival time were 6 and 10.3 months, respectively. Myelosuppression was unusually severe, with granulocyte counts < 1000/mm3 in 65% of patients, including four patients with granulocyte count nadirs < 100/mm3. Three patients developed granulocytopenic fever, with two drug-related deaths (sepsis, hyperosmolar coma). Nearly all patients had nausea and vomiting, but this was not a treatment-limiting toxic effect in any patient. Although this combination suggests a higher response rate than usually seen with bolus iv 5-FU in colon cancer, a trial comparing 5-FU alone or with cisplatin to determine whether true synergy exists is currently underway.

Original languageEnglish (US)
Pages (from-to)1359-1363
Number of pages5
JournalCancer Treatment Reports
Volume69
Issue number12
StatePublished - Dec 1 1985

Fingerprint

Fluorouracil
Cisplatin
Colon
Adenocarcinoma
Therapeutics
Granulocytes
Drug Synergism
Leukemia L1210
Poisons
Esophageal Neoplasms
Head and Neck Neoplasms
Coma
Pharmaceutical Preparations
Colonic Neoplasms
Nausea
Vomiting
Sepsis
Fever
Carcinoma
Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cisplatin plus 5-FU for the treatment of adenocarcinoma of the colon. / Loehrer, P. J.; Einhorn, L. H.; Williams, S. D.; Hui, S. L.; Estes, N. C.; Pennington, K.

In: Cancer Treatment Reports, Vol. 69, No. 12, 01.12.1985, p. 1359-1363.

Research output: Contribution to journalArticle

Loehrer, PJ, Einhorn, LH, Williams, SD, Hui, SL, Estes, NC & Pennington, K 1985, 'Cisplatin plus 5-FU for the treatment of adenocarcinoma of the colon', Cancer Treatment Reports, vol. 69, no. 12, pp. 1359-1363.
Loehrer, P. J. ; Einhorn, L. H. ; Williams, S. D. ; Hui, S. L. ; Estes, N. C. ; Pennington, K. / Cisplatin plus 5-FU for the treatment of adenocarcinoma of the colon. In: Cancer Treatment Reports. 1985 ; Vol. 69, No. 12. pp. 1359-1363.
@article{f096f0160fc24751a445f55e5ac6c452,
title = "Cisplatin plus 5-FU for the treatment of adenocarcinoma of the colon",
abstract = "Cisplatin plus 5-FU appears to have significant additive activity in various tumors, such as head and neck carcinoma and esophageal cancer. A partial explanation for this may be drug synergism, which has been noted in the L1210 leukemia model. Based on these data, a prospective trial of weekly bolus 5-FU (15 mg/kg) and cisplatin (60 mg/m2) given every 3 weeks was initiated at Indiana University. Forty-one patients, of whom 38 are fully evaluable for response, were treated with these two drugs. Ten partial and one complete response (complete + partial response rate = 29{\%}) were observed in the 38 evaluable patients. Thirteen additional patients had stable disease for ≥ 3 months. The median durations of remission and survival time were 6 and 10.3 months, respectively. Myelosuppression was unusually severe, with granulocyte counts < 1000/mm3 in 65{\%} of patients, including four patients with granulocyte count nadirs < 100/mm3. Three patients developed granulocytopenic fever, with two drug-related deaths (sepsis, hyperosmolar coma). Nearly all patients had nausea and vomiting, but this was not a treatment-limiting toxic effect in any patient. Although this combination suggests a higher response rate than usually seen with bolus iv 5-FU in colon cancer, a trial comparing 5-FU alone or with cisplatin to determine whether true synergy exists is currently underway.",
author = "Loehrer, {P. J.} and Einhorn, {L. H.} and Williams, {S. D.} and Hui, {S. L.} and Estes, {N. C.} and K. Pennington",
year = "1985",
month = "12",
day = "1",
language = "English (US)",
volume = "69",
pages = "1359--1363",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Cisplatin plus 5-FU for the treatment of adenocarcinoma of the colon

AU - Loehrer, P. J.

AU - Einhorn, L. H.

AU - Williams, S. D.

AU - Hui, S. L.

AU - Estes, N. C.

AU - Pennington, K.

PY - 1985/12/1

Y1 - 1985/12/1

N2 - Cisplatin plus 5-FU appears to have significant additive activity in various tumors, such as head and neck carcinoma and esophageal cancer. A partial explanation for this may be drug synergism, which has been noted in the L1210 leukemia model. Based on these data, a prospective trial of weekly bolus 5-FU (15 mg/kg) and cisplatin (60 mg/m2) given every 3 weeks was initiated at Indiana University. Forty-one patients, of whom 38 are fully evaluable for response, were treated with these two drugs. Ten partial and one complete response (complete + partial response rate = 29%) were observed in the 38 evaluable patients. Thirteen additional patients had stable disease for ≥ 3 months. The median durations of remission and survival time were 6 and 10.3 months, respectively. Myelosuppression was unusually severe, with granulocyte counts < 1000/mm3 in 65% of patients, including four patients with granulocyte count nadirs < 100/mm3. Three patients developed granulocytopenic fever, with two drug-related deaths (sepsis, hyperosmolar coma). Nearly all patients had nausea and vomiting, but this was not a treatment-limiting toxic effect in any patient. Although this combination suggests a higher response rate than usually seen with bolus iv 5-FU in colon cancer, a trial comparing 5-FU alone or with cisplatin to determine whether true synergy exists is currently underway.

AB - Cisplatin plus 5-FU appears to have significant additive activity in various tumors, such as head and neck carcinoma and esophageal cancer. A partial explanation for this may be drug synergism, which has been noted in the L1210 leukemia model. Based on these data, a prospective trial of weekly bolus 5-FU (15 mg/kg) and cisplatin (60 mg/m2) given every 3 weeks was initiated at Indiana University. Forty-one patients, of whom 38 are fully evaluable for response, were treated with these two drugs. Ten partial and one complete response (complete + partial response rate = 29%) were observed in the 38 evaluable patients. Thirteen additional patients had stable disease for ≥ 3 months. The median durations of remission and survival time were 6 and 10.3 months, respectively. Myelosuppression was unusually severe, with granulocyte counts < 1000/mm3 in 65% of patients, including four patients with granulocyte count nadirs < 100/mm3. Three patients developed granulocytopenic fever, with two drug-related deaths (sepsis, hyperosmolar coma). Nearly all patients had nausea and vomiting, but this was not a treatment-limiting toxic effect in any patient. Although this combination suggests a higher response rate than usually seen with bolus iv 5-FU in colon cancer, a trial comparing 5-FU alone or with cisplatin to determine whether true synergy exists is currently underway.

UR - http://www.scopus.com/inward/record.url?scp=0022297692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022297692&partnerID=8YFLogxK

M3 - Article

C2 - 4075311

AN - SCOPUS:0022297692

VL - 69

SP - 1359

EP - 1363

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 12

ER -